How a Personal Tragedy Drove Kiran Mazumdar‑Shaw to Pioneer Cancer Biosimilars at Biocon

When Kiran Mazumdar‑Shaw received the call that her long‑time friend had succumbed to breast cancer, the loss felt like a punch to the gut. The friend, a well‑to‑do professional, had been forced to sell her ancestral home just to keep up with the eye‑watering price of a biologic drug – roughly ₹2.5 lakh per dose.

“She was a successful, affluent woman, yet even she had to mortgage her property,” Mazumdar‑Shaw recalled in a candid conversation with entrepreneur Raj Shamani. “I kept asking myself, why are these lifesaving medicines priced so astronomically?”

That personal anguish became the catalyst for a strategic pivot at Biocon. The company had already earned a reputation for democratising insulin, making a staple for diabetics more affordable across emerging markets. Mazumdar‑Shaw wondered aloud, “If we could break the price barrier for insulin, why not for cancer treatments?”

She challenged her R&D teams to develop a biosimilar for trastuzumab – the blockbuster antibody used in HER2‑positive breast cancer. At the time, the regulatory landscape for biosimilars was murky; there were no clear pathways, and many skeptics thought the endeavour impossible.

Undeterred, the scientists pressed on, guided by the principle that “science will carve the route, and the regulators will follow.” Their perseverance paid off when, in 2017, the U.S. FDA granted Biocon the world’s first approval for a trastuzumab biosimilar. It was a watershed moment, proving that a complex protein‑based therapy could be reproduced at a fraction of the cost without compromising safety or efficacy.

Today, Biocon’s biosimilar portfolio spans insulin, growth hormones, and a growing suite of oncology antibodies. The company’s mantra – “make the essential affordable” – echoes the painful memory of a friend who had to sacrifice everything for a single dose.

“Every patient who gets our biosimilar is a reminder of why we started this journey,” says Mazumdar‑Shaw, her voice tinged with both grief and resolve. “We owe it to them to keep pushing the boundaries of accessibility.”

The story is a stark reminder that behind every scientific breakthrough lies a human narrative – a story of loss, determination, and the relentless pursuit of a world where life‑saving drugs are within reach for all.